Rhumbline Advisers raised its holdings in shares of The Clorox Company (NYSE:CLX – Get Rating) by 6.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 228,445 shares of the company’s stock after acquiring an additional 13,209 shares during the period. Rhumbline Advisers owned approximately 0.19% of Clorox worth $32,206,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of CLX. Park Avenue Securities LLC acquired a new stake in Clorox during the 1st quarter valued at approximately $242,000. Mutual of America Capital Management LLC lifted its stake in shares of Clorox by 1.3% in the 1st quarter. Mutual of America Capital Management LLC now owns 16,499 shares of the company’s stock valued at $2,294,000 after purchasing an additional 211 shares during the period. FDx Advisors Inc. lifted its stake in shares of Clorox by 15.1% in the 1st quarter. FDx Advisors Inc. now owns 1,740 shares of the company’s stock valued at $242,000 after purchasing an additional 228 shares during the period. Metis Global Partners LLC acquired a new position in shares of Clorox in the 1st quarter valued at $270,000. Finally, Mount Yale Investment Advisors LLC lifted its stake in shares of Clorox by 5.1% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 2,574 shares of the company’s stock valued at $358,000 after purchasing an additional 124 shares during the period. 81.69% of the stock is currently owned by institutional investors and hedge funds.
Clorox Price Performance
Clorox stock opened at $149.11 on Thursday. The Clorox Company has a 52-week low of $120.50 and a 52-week high of $186.86. The firm has a market capitalization of $18.40 billion, a price-to-earnings ratio of 45.74, a PEG ratio of 3.15 and a beta of 0.31. The company has a fifty day simple moving average of $138.65 and a 200-day simple moving average of $141.61. The company has a quick ratio of 0.50, a current ratio of 0.88 and a debt-to-equity ratio of 4.99.
Clorox Announces Dividend
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the stock. DA Davidson boosted their target price on shares of Clorox from $124.00 to $155.00 and gave the company a “neutral” rating in a research note on Wednesday, November 2nd. Morgan Stanley boosted their target price on shares of Clorox from $130.00 to $142.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 2nd. Evercore ISI started coverage on shares of Clorox in a research note on Monday, October 17th. They issued an “underperform” rating for the company. Barclays boosted their price target on shares of Clorox from $93.00 to $101.00 and gave the stock an “underweight” rating in a report on Friday, August 19th. Finally, JPMorgan Chase & Co. cut their price target on shares of Clorox from $129.00 to $126.00 and set an “underweight” rating for the company in a report on Thursday, October 13th. Ten research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $135.08.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
- Get a free copy of the StockNews.com research report on Clorox (CLX)
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.